You must be logged in to see Nallasivam Palanisamy's about summary.
Dr. Palanisamy completed his undergraduate and graduate studies at the University of Madras, India. His research interests are focused on the discovery of cancer biomarkers in lymphomas and solid cancers. During his post-doctoral research at the Memorial Sloan-Kettering cancer center, he was involved in the discovery of recurrent gene fusions in follicular and diffuse large B-cell lymphomas. He was the founding director of research and development at Cancer Genetics, Inc (CGIX), where he introduced novel approaches for the development of diagnostic reagents targeting chromosomal translocation in cancer (US Patents # 8945556; 7964345; 7585964). He pioneered the application of next generation sequencing technology for transcriptome sequencing and discovered novel “druggable” gene fusions in prostate cancer, gastric cancer and melanoma (Palanisamy et al., Nat Med 2010). His current research goals are to understand the molecular basis of tumor heterogeneity in solid cancers particularly prostate cancer and its impact in early diagnosis, response to treatment and clinical outcome.
You must be logged in to see Nallasivam Palanisamy's contact details.
You must be logged in to see Nallasivam Palanisamy's education details.
You must be logged in to see Nallasivam Palanisamy's work experience details.